Kulkarni Samarth bought CRSP
March 20, 2026 · Form 4 insider transaction
Kulkarni Samarth bought 19,687 shares of CRISPR Therapeutics AG, a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
19,687
Price
N/A
Total value
N/A
InsiderKulkarni Samarth
RoleOfficer, Director
SecurityCommon Shares
Transaction codeM: Option exercise
Transaction dateMarch 20, 2026
Filing dateMarch 24, 2026
Shares owned after265,521
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.; Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.